DROLOXIFENE IN THE TREATMENT OF METASTATIC BREAST-CANCER

206 postmenopausal women with metastatic breast cancer from 16 European and Brasilian centers were treated with either 20, 40 or 100 mg Droloxifene until disease progression. 69% of the patients had been pretreated with other hormonal agents, chemotherapy, or both. Response rates from intention-to-treat analyses were 16% in the 20-mg group (n=68), 19% in the 40-mg group (n=81), and 14% in the 100-mg group (n=57). Time to disease progression was 4.5 months in the 20-mg group, 4.6 months in the 40-mg group, and 4.4 months in the 100-mg group. For the response rate and the time to progression no statistically significant differences between dose groups were found. Tolerability was equally good for all dose groups.